Company Overview and News

 
What’s Pushing Oil Prices Higher?

20h marketrealist
On May 21, US crude oil July futures rose 1.4% and settled at $72.35 per barrel—the highest closing level for active US crude oil futures since November 26, 2014. On May 14–21, US crude oil July futures rose 1.9%.

 
The Positive Reflexive Feedback Loop Has Started For Energy Stocks

2018-05-21 seekingalpha
Energy sector performance relative to WTI has broken out of a downtrend that's been in place since the start of 2017.

 
Chesapeake Energy Common Is Making Its Move

2018-05-21 seekingalpha
This appears to be a rally for disciplined (expert) traders rather than buy and hold investors.

 
Where Could US Crude Oil Close Next Week?

2018-05-18 marketrealist
On May 17, US crude oil’s implied volatility was 23%, 6.1% lower than its 15-day moving average.

 
Is the Global Oil Supply Shrinking?

2018-05-18 marketrealist
On May 17, US crude oil June futures were unchanged and closed at $71.49 per barrel, their highest close in three and a half years.

 
CRC / California Resources Corp. / Chevron Corp - SC 13G/A (Passive Investment)

2018-05-17 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
CRC / California Resources Corp. / Chevron Corp - SC 13G/A (Passive Investment)

2018-05-17 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Is Las Vegas Sands (LVS) Outperforming Other Consumer Discretionary Stocks This Year?

2018-05-17 zacks
Investors focused on the Consumer Discretionary space have likely heard of Las Vegas Sands (LVS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of LVS and the rest of the Consumer Discretionary group's stocks.

7
Tracking George Soros' Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.

 
Has Western Digital (WDC) Outpaced Other Computer and Technology Stocks This Year?

2018-05-17 zacks
Investors focused on the Computer and Technology space have likely heard of Western Digital (WDC - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Computer and Technology peers, we might be able to answer that question.

 
Is Rocky Brands (RCKY) Stock Outpacing Its Consumer Discretionary Peers This Year?

2018-05-17 zacks
Investors interested in Consumer Discretionary stocks should always be looking to find the best-performing companies in the group. Has Rocky Brands (RCKY - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

 
Has Texas Instruments (TXN) Outpaced Other Computer and Technology Stocks This Year?

2018-05-17 zacks
Investors focused on the Computer and Technology space have likely heard of Texas Instruments (TXN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Computer and Technology sector should help us answer this question.

 
BioLife Solutions (BLFS) Shares March Higher, Can It Continue?

2018-05-17 zacks
As of late, it has definitely been a great time to be an investor in BioLife Solutions, Inc. (BLFS - Free Report) . The stock has moved higher by 17.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

 
Can The Uptrend Continue for ChemoCentryx (CCXI)?

2018-05-17 zacks
Investors certainly have to be happy with ChemoCentryx, Inc. (CCXI - Free Report) and its short term performance. After all, the stock has jumped by 13.5% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for CCXI?

 
Will NMI Holdings (NMIH) Continue to Surge Higher?

2018-05-17 zacks
As of late, it has definitely been a great time to be an investor in NMI Holdings, Inc. (NMIH - Free Report) . The stock has moved higher by 20.8% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 13057Q107